Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.48 |
| ▸ | CNR2 | P34972 | 4/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321810 | 1.00 | CNR1 (0.48) | CNR1CNR2TRPV1HTR2CMAP3K14 | |
| SCHEMBL3409160 | 0.87 | CNR1 (0.48) | CNR1CNR2TRPV1HTR2CHTR2A | |
| SCHEMBL6024993 | 0.87 | CNR1 (0.48) | CNR1CNR2TRPV1HTR2CHTR2A | |
| SCHEMBL20554133 | 0.84 | CNR1 (0.42) | CNR1CNR2TRPV1 | |
| SCHEMBL30132623 | 0.84 | CNR1 (0.42) | CNR1CNR2TRPV1 | |
| SCHEMBL25660453 | 0.82 | HTR2C (0.36) | CNR1CNR2TRPV1HTR2CHTR2A | |
| SCHEMBL3326358 | 0.82 | TRPV1 (0.44) | CNR1CNR2TRPV1HTR2CHTR2A | |
| SCHEMBL15021657 | 0.82 | TRPV1 (0.44) | CNR1CNR2TRPV1HTR2CHTR2A | |
| SCHEMBL15054211 | 0.82 | TRPV1 (0.44) | CNR1CNR2TRPV1HTR2CHTR2A | |
| SCHEMBL3322394 | 0.82 | TRPV1 (0.46) | CNR1CNR2TRPV1HTR2CMAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107405337-B | Substituted chromans and methods of use | 艾伯维公司 | 2021-02-09 | — | — | CN | disclosed |
| EP-3212189-B1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE OVERSEAS SÀ RL (LU) | 2020-09-09 | — | — | EP | disclosed |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2019-05-02 | — | — | US | disclosed |
| CN-107405337-A | Substituted chroman and application method | 艾伯维公司 | 2017-11-28 | — | — | CN | disclosed |
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE S À R L (LU) | 2017-07-06 | — | — | US | disclosed |
| US-9642831-B2 | Substituted chromanes and method of use | ABBVIE S.Á.R.L. (LU) | 2017-05-09 | — | — | US | disclosed |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE GLOBAL LIMITED (BM) | 2016-05-05 | — | — | US | disclosed |
| US-8969325-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969325-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8859584-B2 | TRPV1 antagonists | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013096223-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158067-A1 | TRPV1 Antagonists | ABBVIE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| EP-1716141-A1 | BENZOPYRAN DERIVATIVES, METHOD OF PRODUCTION AND USE THEREOF | Université de Liège (BE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005075463-A1 | BENZOPYRAN DERIVATIVES, METHOD OF PRODUCTION AND USE THEREOF | UNIVERSITE DE LIEGE (BE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | CNR1 22/4885CNR2 18/4885TRPV1 1/4885 |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | TRPV1, MRGPRX1, MRGPRX4 | CNR1 22/4885CNR2 33/4885TRPV1 1/4885 |
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | CNR1 251/4885CNR2 567/4885TRPV1 1470/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | CNR1 22/4885CNR2 18/4885TRPV1 1/4885 |
| US-20130158067-A1 | TRPV1 Antagonists | TRPV1, NPY1R, MRGPRX1 | CNR1 27/4885CNR2 36/4885TRPV1 1/4885 |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | CNR1 251/4885CNR2 567/4885TRPV1 1470/4885 |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | CFTR, CHRM3, CHRM2 | CNR1 251/4885CNR2 567/4885TRPV1 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.